FREE Webinar
Tuesday, July 28, 2020
2:30 - 4:00 PM, Eastern Standard Time
SARS-CoV-2 is characterized by its rapid spread and significant human-to-human transmission. With no approved vaccines or treatments yet available, researchers are exploring various medical interventions, including neutralizing monoclonal antibodies (mAbs), to control the global COVID-19 pandemic. The SARS-CoV-2 spike (S) glycoprotein, which promotes entry into host cells, is the main target of neutralizing antibodies. In this multisponsored webinar by The Scientist, a panel of researchers will discuss potential neutralizing antibodies currently under investigation for SARS-CoV-2 treatment.
Topics to be covered
- Human monoclonal antibodies for SARS-CoV-2
- SARS-CoV-2 neutralizing antibodies for global access
Meet the Speakers:
James E. Crowe, Jr., MD
Director, Vanderbilt Vaccine Center
Professor, Pediatrics and Pathology, Microbiology and Immunology
Ann Scott Carrell Chair
Devin Sok, PhD
Senior Director, Antibody Discovery and Development
IAVI
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
